Gallbladder carcinoma (GBC) is a chronic malignancy of the gall bladder and intrahepatic and extrahepatic common bile ducts with a high mortality rate and forms the fifth common cancer of gastrointestinal tract globally. Women remain at higher risk than men and recent studies have reported the highest rate of incidence in women from Delhi, India. GBC treatment suffers from the disadvantage of lack of suitable biomarkers for early diagnosis of the disease. Running title: Proteomic studies in Gallbladder Cancer: Recent Developments
Introduction
Gallbladder carcinoma (GBC) is an adenocarcinoma of epithelial tissues of gall bladder and involves a chronic biliary tract malignancy with a high mortality rate. Reported as one of the most aggressive carcinomas (Sahasrabuddhe et al., 2014) , it is also reported as the fifth common cancer of gastrointestinal tract (Huang et al., 2014) . Globally, occurrence of GBC have been reported to be higher in East Asia including Korea and Japan and Eastern Europe extending across Slovakia, Poland and Czech Republic (World Cancer Report, 2008) . Women are at 5 folds higher risk as compared to men in high-risk zones encompassing Pakistan, India, Spain and Colombia (World Cancer Report, 2008) . It is also reported to be the most common cause of cancer related mortality in Northern and North-eastern parts of India (Barbhuiya et al., 2008; Singh et al., 2014) . According to recent report, the highest rate of incidence of GBC has been reported in women from Delhi, India (21.5/1,00,000) followed by South Karachi, Pakistan (13.8/1,00,000) and Quito, Ecuador (12.9/1,00,000) while the highest mortality has been reported from Chile with higher mortality rate in men (7.8/1,00,000) as compared to that of women (16.6/1,00,000) (Barbhuiya et al., 2008; Singh et al., 2014). The major challenges associated with this disease are the lack of suitable specific markers for its early detection and diagnosis. Although several markers have been tested, there still remains a dearth of specific effective markers for early diagnosis in GBC. Therefore the study of gall bladder cancer finds importance in the current day across the globe. Recent proteomics approaches are now being employed and act as promising tools towards early diagnosis. In this review we focus on the recent developments in the field of GBC with reference to its (i) risk factors in GBC, (ii) diagnosis and treatment, (iii) molecular markers, and (iv) proteomic studies in GBC. 
Diagnosis and Treatment
The appearance of symptoms is progression-stage-dependent, and mostly appears during advanced metastasis. Therefore it is difficult to detect the cancer at an earlier stage and treat protein is reported to be down regulated in the GBC patients as compared to the normal volunteers (Huang et al., 2014) . Surface-enhanced laser desorption/ionization (SELDI) [44] confirmed that upregulated expression of ANXA4 and decreased expression of Hsp90β and Dync1h1 is a significant biomarker in GBC carcinoma (Huang et al., 2014 ). S100A10, a member of the S100 (SP) family is a multifunctional signaling protein involved in numerous cellular functions such as protein phosphorylation, enzyme activation, calcium homeostasis and interaction with cytoskeletal component (Donato, 2003) . It is also reported to regulate cellular processes like cell growth, cell cycle progression, differentiation, transcription and secretion (Salama et al., 2008) . Over expression of this protein has been shown to result in increased metastasis (Tan et al., 2011) . Increased expression of SA100A10 in the patients with 
Discussion
GBC is one of the most aggressive carcinomas, though rare it has a higher mortality rate among all other biliary tract malignancies. GBC also has a poor prognosis and poor survival rates and suffers from lack of markers capable of early diagnosis of the disease. Due to poor understanding of risk factors and biomarkers for early diagnosis, GBC still remains a major area of research. Although several genetic markers and protein marker are being tested of their potential in detection of GBC, no single marker has enabled its early detection. Thus, a study regarding the proteome analysis in patients suffering from GBC seems imperative. This finds importance in designing clinical strategies against the disease and to find out the novel candidate that can act as potential diagnostic and prognostic marker for GBC. Occurrence of GBC tends to be more in females than in males. Formation of gallstones and cholelithiasis are the potential risk factors of GBC, thus they are considered to be precancerous lesions for GBC (World Cancer Report, 2008) . In this study, we have summarized recent proteomic studies performed in GBC and the importance of potential biomarkers for the diagnosis and prognosis of GBC. Protein markers such as ANXA4, Hsp90B, Dync1h1, S100A10, haptoglobin, prosaposin and transgelin were reported as novel biomarkers (Table 1) using different proteomic studies (Table 1) .
This review summarizes on proteomics study performed to find out novel candidates that could effectively serve as prognostic and diagnostic biomarkers in gallbladder carcinoma. The future scope of this review remains in designating essential biomarkers in GBC with large-scale clinical applications for early detection and improved prognosis for GBC and targeting these biomarkers proving as essential therapeutics for treatment of GBC. Abbreviations used in Table 1 
